BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (NASDAQ: TRCA) today announced that the Company has begun dosing the first patient in a Phase II clinical study evaluating the combination of Genentech, Inc.’s recombinant human growth hormone Nutropin AQ® (somatropin [rDNA origin]) and Tercica’s recombinant insulin-like growth factor-1 Increlex® (mecasermin [rDNA origin] injection). The primary objective of this trial is to assess the efficacy, measured as first-year height velocity, and safety of three different combination regimens of growth hormone and IGF-1 compared to growth hormone alone in the treatment of short stature associated with IGF-1 deficiency.
